Bioavailability

Bioavailability is the proportion of a substance's dose that actually enters the bloodstream in an active, unaltered form and is therefore able to exert an effect. A dose of 100 mg with 50% bioavailability delivers only 50 mg to systemic circulation — the rest is lost before it can act.

The concept sits at the core of pharmacology because it explains why the same substance, at the same dose, can feel dramatically different depending on how it is taken. Route of administration is the single biggest variable governing it.

How it works · its role

When a substance is swallowed, it must survive the digestive environment, cross the gut wall, and then pass through the liver before reaching general circulation. The liver often chemically modifies or breaks down a significant portion of the absorbed dose on this first pass — a process called first-pass metabolism. Substances with extensive first-pass metabolism have low oral bioavailability as a result.

Other routes sidestep the liver to varying degrees. Inhalation delivers a substance directly to the lungs and into the bloodstream almost immediately, with little first-pass loss. Sublingual and buccal absorption (under or inside the cheek) pass through the oral mucosa into blood vessels that bypass the gut-liver pathway. Intranasal (insufflation) absorption is partial — some enters the bloodstream via nasal mucosa, some drains to the stomach and undergoes first-pass metabolism.

Intravenous administration is defined as 100% bioavailability, since the substance enters circulation directly. All other routes fall somewhere below that ceiling.

Relevance to substances & effects

Bioavailability shapes the practical experience of almost every substance in this encyclopedia. A compound with poor oral bioavailability may feel weak or slow to onset when swallowed, yet potent and rapid when inhaled or taken sublingually — even at the same nominal dose.

Opioids illustrate this clearly: several members of the class have bioavailability that differs sharply between oral and other routes, which influences both clinical dosing and risk profile. Cannabis demonstrates a different pattern — inhaled cannabis reaches peak blood levels within minutes, while oral cannabis products (edibles) have a delayed and sometimes unpredictable onset because they undergo first-pass hepatic conversion.

Psychedelics vary widely too. Some are poorly absorbed orally without an enzymatic inhibitor to protect them from gut breakdown; others are active at low doses by almost any route. For harm-reduction purposes, understanding that a route change is not a simple 1-to-1 dose rescaling — bioavailability differences can be large — helps explain why dose errors most often occur when someone switches how they take a substance.